MedTrace Logo

Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor

NCT05361655 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2888

Last updated 2024-06-07

Study results available
· View outcomes & findings →

Summary

A retrospective study of de-identified (to preserve patient privacy) patient information from the Flatiron Health Analytic Database to compare effectiveness (i.e., overall survival) of first line palbociclib + aromatase inhibitor (AI) versus AI alone treatment in postmenopausal women or men with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (MBC) in the United States clinical practices.

Conditions

Interventions

DRUG

Palbociclib + an aromatase inhibitor

Palbociclib + an aromatase inhibitor therapy

DRUG

Aromatase inhibitor

Aromatase inhibitor therapy

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2021-09-01
Completion
2021-09-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05361655 on ClinicalTrials.gov